Psoriasis

The AJMC® Psoriasis compendium is a comprehensive resource for clinical news and expert insights for the chronic skin disease, which tends to go through cycles where it flares and goes into remission.

Latest News

Cardiovascular heart arteries AI - hirakun - AdobeStock_1191397495 (1).jpeg
Diabetes Increases Cardiovascular Risk in Patients With Psoriasis, Coronary Artery Disease

July 16th 2025

New research identifies diabetes as an independent predictor of major adverse cardiovascular events in patients with both psoriasis and coronary artery disease.

Psoriasis in people with skin of color. | Image credit: Seventyfour - stock.adobe.com
Guselkumab Clears Scalp Psoriasis Across All Skin Tones

July 14th 2025

Psoriasis | Image credit: fusssergei - stock.adobe.com
Risankizumab Found Effective in Patients With Moderate Plaque Psoriasis

July 8th 2025

Plaque psoriasis | Image credit: Milan Lipowski - stock.adobe.com
Defining On-Treatment Remission in Plaque Psoriasis

June 18th 2025

Adalimumab | Image credit: luchschenF - stock.adobe.com
Methotrexate Adds No Benefit to Adalimumab in Psoriasis Treatment, Study Suggests

June 16th 2025

A Personalized Approach to Disease Management in Psoriasis

A panel of experts discuss their personalized approaches to treating patients with psoriasis and comorbidities such as metabolic syndrome.

Ryan Haumschild, PharmD, MS, MBA, Bhavesh Shah, PharmD, Mark Lebwohl, MD, and Robert Groves, MD.
Continuing Medical Education
View All
July 17th 2025

Advancing Patient Outcomes in Hidradenitis Suppurativa: Updates and Strategies for Managed Care

1.5 Credits / Dermatology
July 17th 2025

Treatment Gaps in the Management of Generalized Pustular Psoriasis: Enhancing the Role of Managed Care

1.5 Credits / Dermatology, Immunology
July 17th 2025

The Economics of Transthyretin-Mediated Amyloidosis: Balancing Equity and Access in Resource Allocation

1 Credit / Cardiology, Neurology
July 17th 2025

Advancing Immunotherapy in Endometrial Cancer: A Managed Care Perspective on Personalized Care

1.5 Credits / Gynecologic Cancer, Health Equity, Diversity & Inclusion, Oncology, Women's Health

More News

Guselkumab | Image credit: luchschenF - stock.adobe.com
Published: October 25th 2024 | Updated: October 25th 2024

Guselkumab Clears Skin in Psoriasis Resistant to Topicals

Pearl Steinzor
New phase 3b data reveal significant skin clearance in historically underserved patients with moderate plaque psoriasis, offering hope for improved treatment outcomes.
Heart - Elena - stock.adobe.com.jpg
October 9th 2024

Exploring the Genetic Link Between Cardiovascular Disease and Psoriasis

Pearl Steinzor
Study findings reveals a 1-way relationship between cardiovascular disease and psoriasis, with no impact on other immune-mediated inflammatory diseases.
Psoriasis - SergeVo - stock.adobe.com.png
October 4th 2024

Twice-Daily ESK-001 Treatment Shows Majority of Psoriasis Patients Achieve PASI 75

Tim Smith
These 28-week data on twice-daily ESK-001 highlight the drug’s safety and efficacy among patients with psoriasis.
Woman receives phototherapy | Image credit: dikushin - stock.adobe.com
September 25th 2024

Home-Based Phototherapy for Psoriasis as Effective as Office-Based Treatment With Less Patient Burden

Pearl Steinzor
Many patients struggle with therapeutic control, adverse effects, and costs of psoriasis treatments, prompting a renewed focus on alternative treatments like phototherapy.
Psoriasis concept on skin of color | Image credit: CandyRetriever - stock.adobe.com
September 19th 2024

Black Individuals Have Higher Odds of Receiving Skin Biopsies for Psoriasis

Pearl Steinzor
Findings from a new study reveal significant racial differences in skin biopsy frequency for psoriasis diagnosis, indicating potential diagnostic challenges, particularly for Black patients.
Psoriasis | image credit: pimentos – stock.adobe.com.jpg
August 28th 2024

TYK2 Inhibitor Zasocitinib Shows High Efficacy, Safety in Moderate to Severe Psoriasis

Pearl Steinzor
A phase 2b clinical trial demonstrates the potential of zasocitinib in achieving biologic-level efficacy with minimal adverse effects.
Apremilast | luchschenF - stock.adobe.com
August 20th 2024

Apremilast Now Available in US for Pediatric Plaque Psoriasis

Pearl Steinzor
Amgen announces new FDA-approved oral treatment option for children and adolescents with moderate to severe plaque psoriasis.
Guselkumab | Image credit: luchschenF - stock.adobe.com
August 6th 2024

Extended Guselkumab Dosing Every 16 Weeks Proven Effective for Psoriasis Maintenance

Pearl Steinzor
This new study confirms the noninferiority of extended dosing intervals for psoriasis control in super responders.
TikTok App on Smartphone | Image credit: nikkimeel - stock.adobe.com
August 1st 2024

Social Media and Psoriasis: Tackling Misinformation on TikTok

Maddi Hebebrand
A recent study found psoriasis content deemed “unreliable” still obtained 850,000 likes.
Blood sample collection | Image credit: luchschenF - stock.adobe.com
July 30th 2024

Inflammatory Markers Predict Treatment Response to Biologics in Psoriasis

Pearl Steinzor
Inflammatory markers can indicate treatment efficacy and predict super-responder status in patients with psoriasis treated with biologics, according to one study.
Hand with psoriasis | Ольга Тернавская - stock.adobe.com
July 24th 2024

Smoking, Age, BMI, Previous Exposure Impact Response to Biologics for Psoriasis

Pearl Steinzor
Biologic therapies may be less effective in patients with certain clinical characteristics, a meta-analysis found.
Child's hand with psoriasis | Imaged credit: Ruslan Ivantsov - stock.adobe.com
July 18th 2024

Ixekizumab Improves Children’s Dermatology Life Quality Index Over 2 Years

Pearl Steinzor
Patients with moderate-to-severe plaque psoriasis experienced early and sustained improvements through 108 weeks of treatment.
Psoriasis - SergeVo - stock.adobe.com.png
July 1st 2024

Older Age Linked to Shorter Interval Between Psoriasis, Psoriatic Arthritis

Pearl Steinzor
Patients with a later onset of psoriasis (PsO) may benefit from earlier screening for psoriatic arthritis (PsA), according to one study.
woman with psoriasis | Andrey Popov - stock.adobe.com
June 27th 2024

Two-Way Association Identified Between Psoriasis, Asthma

Pearl Steinzor
A bidirectional risk between psoriasis and asthma has been identified, according to one study.
Psoriasis. Acute psoriasis on the knees, body, elbows is an autoimmune, incurable dermatological skin disease | nuzza11 - stock.adobe.com
Published: June 21st 2024 | Updated: June 21st 2024

Autoimmune Diseases Prevalent Among Patients With Psoriasis, Study Finds

Pearl Steinzor
Researchers have identified a link between psoriasis and the autoimmune diseases hypothyroidism and alopecia areata.
Woman with psoriasis | Andrey Popov - stock.adobe.com
June 10th 2024

Biological Agents More Effective Than Methotrexate in PsA Prevention

Pearl Steinzor
Researchers evaluated the impact of different treatment modalities in the prevention of psoriatic arthritis (PsA).
Doctor examines patient with psoriasis rash | ARTFULLY-79 - stock.adobe.com
June 7th 2024

Weekend Cyclosporine Is Effective, Safe as Maintenance Therapy for Psoriasis

Pearl Steinzor
Patients with moderate to severe psoriasis may benefit from weekend cyclosporine treatment (WCT) as a maintenance therapy, according to one study.
A dermatologist wearing gloves examines the skin of a sick patient. Examination and diagnosis of skin diseases-allergies, psoriasis, eczema, dermatitis | Image credit: fusssergei - stock.adobe.com
May 21st 2024

Low Stress Resilience Associated With Psoriasis Among Men, Study Shows

Pearl Steinzor
Psychological well-being should be considered in the management of psoriasis, research indicates.
Doctor treats nail psoriasis | Image Credit: © fusssergei - stock.adobe.com
May 14th 2024

BoNT-A Injection Shows Prolonged Efficacy in Patients With Nail Psoriasis, Study Finds

Pearl Steinzor
Botulinum toxin A (BoNT-A) exhibited promising results for nail psoriasis for up to 6 months with a single injection.
Doctor at appointment shows patient printed fragment of examination, where joint disease is recorded | shidlovski - stock.adobe.com
April 22nd 2024

Risankizumab Shows Efficacy in Patients With Active Psoriatic Arthritis Through 52 Weeks

Pearl Steinzor
Efficacy results support long-term use of risankizumab in patients with active psoriatic arthritis across multiple patient and psoriatic disease characteristics.
Psoriasis treatment concept | Sviatlana - stock.adobe.com
April 18th 2024

Many Patients With Psoriasis in Clinical Trials Experience Nocebo Effects, Study Finds

Pearl Steinzor
Half of patients exposed to placebo in clinical trials experienced adverse events (AEs), which may be partially explainable by nocebo effects, according to a recent review and meta-analysis.
A dermatologist wearing gloves examines the skin of a sick patient. Examination and diagnosis of skin diseases-allergies, psoriasis, eczema, dermatitis | Image credit: fusssergei - stock.adobe.com
April 9th 2024

Guselkumab Shows High Efficacy in Patients With Psoriasis, History of Cancer

Pearl Steinzor
Patients with moderate to severe psoriasis and a history of cancer have improved symptoms and a favorable safety profile with guselkumab treatment, according to a new study.
Hand with psoriasis | Ольга Тернавская - stock.adobe.com
April 2nd 2024

Roflumilast Cream Is Well Tolerated, Efficacious in Patients With Chronic Plaque Psoriasis

Pearl Steinzor
Roflumilast cream may be suitable for chronic treatment, including the face and intertriginous areas, according to one study.
Psoriasis - SergeVo - stock.adobe.com.png
March 28th 2024

Undertreatment, Biologic Access Gaps Identified in Psoriasis Treatment

Pearl Steinzor
Posters presented at the American Academy of Dermatology Annual Meeting identified significant undertreatment of psoriasis and significant gaps in biologic medication treatment.
Psoriasis vulgaris on the male hands with plaque, rash and patches, isolated on white background.| Ban - stock.adobe.com
March 18th 2024

Brodalumab Is Effective, Safe in Patients With Moderate to Severe Psoriasis

Pearl Steinzor
Posters presented at the American Academy of Dermatology Annual Meeting demonstrated both short- and long-term efficacy and safety profiles of brodalumab in patients with moderate to severe psoriasis.
Psoriasis skin, eczema, rash and other skin diseases. A woman hides her face, she is ashamed of her autoimmune genetic disease. Imperfect beauty. | Image credit: stockmaster - stock.adobe.com.jpg
March 15th 2024

Improvements in Pain, Physical Function Achieved With Guselkumab in Patients With Treatment-Resistant PsA

Pearl Steinzor
Patients experienced clinically meaningful improvements in health-related quality of life (HRQoL) factors after 6 months of guselkumab, according to one study.
A man applies topical cream to plaque psoriasis patch on arm | Image Credit: © Olga - stock.adobe.com
March 13th 2024

Quality of Life, Severity Scales Correlated in Patients With Psoriasis Worldwide

Christina Mattina
Study findings show that scores on the Psoriasis Area and Severity Index and the Dermatology Quality of Life Index are correlated in patients with psoriasis across several continents, but factors affecting each of these scores are different across countries.
Psoriasis treatment concept | Image credit: Sviatlana - stock.adobe.com
February 21st 2024

Study Finds Efficiency Frontier Approach Provides Solution to High Drug Prices for Psoriasis in the US

Pearl Steinzor
Researchers suggest an alternative method to align drug prices with clinical benefits for patients with psoriasis.
Psoriasis skin. Closeup of rash and scaling on the patient's skin. The concept of chronic disease treatment. Dermatological problems | IIIRusya - stock.adobe.com
February 14th 2024

Risks of Melanoma, Other Skin Cancers Are Higher in Patients Treated With Biologics for Psoriasis

Pearl Steinzor
It is important to study the safety of targeted therapies in populations at increased risk of skin cancer, according to the researchers.
Elderly man suffering from psoriasis on hands | and.one - stock.adobe.com
February 12th 2024

Risankizumab Shown Effective With No Increase in Adverse Events vs Placebo in PsA

Pearl Steinzor
Risankizumab is an effective treatment option for patients with psoriatic arthritis (PsA), according to a recent meta-analysis.
<12345678
...
15>

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo